Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inyta

- PMLiVE

Pfizer turns to cancer immunotherapies

Signs deal with French company Cellectis

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

National Institute for Health and Care Excellence NICE logo

NICE guidelines on statins will ‘medicalise’ the healthy, say doctors

Prominent physicians call for rethink on plans to lower treatment threshold

- PMLiVE

Pfizer appoints diabetes expert Morris Birnbaum

He takes up post as chief scientific officer for cardiovascular and metabolic diseases

National Institute for Health and Care Excellence NICE logo

NICE denies Stelara’s use in psoriatic arthritis

Refuses to extend NHS-recommended indications of Janssen drug

- PMLiVE

Oxford PharmaGenesis launches its new HealthScience approach

Unveils integrated approach to engaging physicians, patients and policy-makers

National Institute for Health and Care Excellence NICE logo

NICE backs reimbursement of Sanofi’s MS drug Lemtrada

Final guidance opens doors for use on NHS in England and Wales

- PMLiVE

Pfizer abandons AZ takeover bid – for now

Deadline for deal passes after four rejected offers

- PMLiVE

No mass revolt from AZ shareholders on Pfizer takeover

Company’s decision to stand firm is applauded by investors

- PMLiVE

Nothing makes sense

Evolutionary theory helps us understand and adapt to the current deal-making frenzy

- PMLiVE

Unions blast ‘negative consequences’ for Sweden of a Pfizer-AZ deal

Say proposed takeover posed an imminent risk to country's life science sector

- PMLiVE

Eisai resubmits Fycompa to G-BA for pricing assessment

But German distribution of epilepsy drug remains on hold until reimbursement settled

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links